GlassScriptPhysician profile
Merna Armanious
NPI 1649698861
$3,202.01
in general payments reported to CMS, 2019-2025
30 companies · $325 in 2025
The $325 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2021: $724 · 2022: $358 · 2023: $974 · 2024: $452 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,750.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $483.53 | 2021-2024 | |
| Abbott Laboratories | $367.19 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Freestyle Libre 2 |
| Amgen INC. | $310.67 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $305.82 | 2022-2025 | Wegovy |
| Medtronic, INC. | $223.55 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $182.45 | 2022-2023 | Farxiga, Andexxa |
| Pfizer INC. | $162.98 | 2023-2025 | |
| Atricure, INC. | $136.07 | 2023 | |
| Lilly USA, LLC | $130.93 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Teva Pharmaceuticals USA, INC. | $124.99 | 2019 | |
| Boston Scientific Corporation | $96.92 | 2022-2025 | Watchman Flx, Latitude Communicator Power Supply, Lux-Dx Insertable Cardiac Monitor |
| Astellas Pharma US INC | $91.83 | 2019 | |
| Shield Therapeutics INC | $73.00 | 2023 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.64 | 2023-2024 | Xifaxan |
| Daiichi Sankyo INC. | $53.26 | 2024 | Injectafer |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $44.54 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.97 | 2023 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $38.56 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.58 | 2022 | |
| Abbvie INC. | $33.11 | 2024 | |
| Merck Sharp & Dohme LLC | $32.86 | 2025 | Winrevair |
| Janssen Pharmaceuticals, INC | $24.17 | 2024 | Xarelto |
| Chiesi USA, INC. | $23.61 | 2022 | |
| Mannkind Corporation | $21.00 | 2025 | |
| Glaxosmithkline, LLC. | $16.40 | 2023 | Trelegy Ellipta |
| Lucid Diagnostics INC. | $16.15 | 2023 | |
| Currax Pharmaceuticals LLC | $15.82 | 2024 | Contrave |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.82 | 2025 | Lifevest |
| Esperion Therapeutics, INC. | $13.80 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.79 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merna Armanious listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.